It is more or less certain that Indian companies cannot repeat their relatively early success in chemical generics with biosimilars on the global stage. Indian biosimilars will sell - make no mistake. But it will likely be a whole bunch of large pharma and biotech companies like Merck, and Biogen selling them under their label. Why do … Continue reading Biotech blues
Apothecurry 